Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
- PMID: 8107199
- PMCID: PMC236588
- DOI: 10.1128/JVI.68.3.1342-1349.1994
Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
Abstract
Neutralizing antibody responses to human immunodeficiency virus type 1 (HIV-1) vary widely and have not been reproducibly associated with prognosis or disease progression. We have found that both low-passage clinical isolates and laboratory-adapted strains of HIV-1 have different sensitivities to neutralization by the same antiserum, depending on the host cell in which the viral stock is prepared. One such isolate (VL069) grown in H9 cells was neutralized by 20 human sera at a geometric mean titer of 1:2,047; this same isolate prepared in peripheral blood mononuclear cell (PBMC) culture was neutralized at a mean titer of < 1:10 by the same sera. Adsorption and mixing experiments indicated that neither antibody to H9 cell components nor blocking by excess viral antigen was responsible for the differences observed. This host cell effect is rapidly reversible upon passage of the virus from PBMCs to H9 cells and back into PBMCs. In contrast, the neutralization characteristics remained remarkably stable over extended culture in PBMCs. Two laboratory strains and five clinical isolates were evaluated in expanded studies of this phenomenon. While the neutralization characteristics of most of the strains studied were affected by the host cell in which the strain was propagated, two of the strains (one clinical isolate and one laboratory strain) appeared antigenically unaffected by their cell of origin. Host cell effect was also evident in neutralization by monoclonal antibodies directed against the CD4-binding region and the V2, V3, and gp41 regions. Possible mechanisms for this host cell effect include (i) mutation during passaging; (ii) selection in different host cells of different subpopulations of the (uncloned) viral stock; and (iii) cell-specific posttranslational modifications. To explore these possibilities, the V3 through V5 region of gp120 was sequenced in preparations made by passing VL069 into H9 cells and into PBMCs; HIVMN grown in CEM-SS cells and in PBMCs was also sequenced. In both cases, a few amino acid changes outside the V3 region were found. Studies are currently under way to assess the significance of these changes.
Similar articles
-
Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.J Virol. 1998 Sep;72(9):7099-107. doi: 10.1128/JVI.72.9.7099-7107.1998. J Virol. 1998. PMID: 9696803 Free PMC article.
-
Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.J Virol. 1996 Jul;70(7):4466-73. doi: 10.1128/JVI.70.7.4466-4473.1996. J Virol. 1996. PMID: 8676471 Free PMC article.
-
N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.J Virol. 2004 Apr;78(7):3279-95. doi: 10.1128/jvi.78.7.3279-3295.2004. J Virol. 2004. PMID: 15016849 Free PMC article.
-
Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.Virology. 1997 Nov 24;238(2):254-64. doi: 10.1006/viro.1997.8812. Virology. 1997. PMID: 9400598
-
Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.Virology. 1997 Mar 17;229(2):360-9. doi: 10.1006/viro.1997.8443. Virology. 1997. PMID: 9126249
Cited by
-
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.J Virol. 2002 Mar;76(5):2233-44. doi: 10.1128/jvi.76.5.2233-2244.2002. J Virol. 2002. PMID: 11836401 Free PMC article.
-
What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Rigorous Simian Immunodeficiency Virus Vaccine Trials Can Be Instructive.Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):a029504. doi: 10.1101/cshperspect.a029504. Cold Spring Harb Perspect Biol. 2018. PMID: 28348034 Free PMC article. Review.
-
HIV-1 neutralizing antibodies: understanding nature's pathways.Immunol Rev. 2013 Jul;254(1):225-44. doi: 10.1111/imr.12075. Immunol Rev. 2013. PMID: 23772623 Free PMC article. Review.
-
Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.EBioMedicine. 2016 Jun;8:237-247. doi: 10.1016/j.ebiom.2016.04.040. Epub 2016 May 5. EBioMedicine. 2016. PMID: 27428434 Free PMC article.
-
Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex.Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10367-72. doi: 10.1073/pnas.96.18.10367. Proc Natl Acad Sci U S A. 1999. PMID: 10468614 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials